WilmerHale Represents Viamet Pharmaceuticals in Acquisition by NovaQuest Capital Management

WilmerHale Represents Viamet Pharmaceuticals in Acquisition by NovaQuest Capital Management

Firm News

Viamet Pharmaceuticals (NC), Inc. (Viamet Pharmaceuticals) today announced that it has entered into an agreement with NovaQuest Capital Management, L.L.C. (NovaQuest Capital) for the acquisition of Viamet Pharmaceuticals, including the company's product candidate, VT-1161, which successfully completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis and onychomycosis. Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets.

The WilmerHale deal team representing Viamet Pharmaceuticals includes Rosemary Reilly, Andrew Bonnes, Steve Barrett, Rob Burke, Kimberly Wethly, Mark Nylen, Andrea Sorrentino, Erin Garrity, Paul Jakubowski and Amit Tantri.

Read Viamet Pharmaceuticals' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.